Mizolastine

Mizolastine

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	By mouth (tablets)
ATC code	R06AX25 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Identifiers
IUPAC name 2-[{1-[1-(4-Fluorobenzyl)-1H-benzimidazol-2-yl]piperidin-4-yl}(methyl)amino]pyrimidin-4(1H)-one
CAS Number	108612-45-9 Y
PubChem CID	65906
ChemSpider	59315 N
UNII	244O1F90NA
KEGG	D01117 Y
ChEMBL	ChEMBL94454 N
CompTox Dashboard (EPA)	DTXSID5046801
ECHA InfoCard	100.149.406
Chemical and physical data
Formula	C24H25FN6O
Molar mass	432.503 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
InChI InChI=1S/C24H25FN6O/c1-29(23-26-13-10-22(32)28-23)19-11-14-30(15-12-19)24-27-20-4-2-3-5-21(20)31(24)16-17-6-8-18(25)9-7-17/h2-10,13,19H,11-12,14-16H2,1H3,(H,26,28,32) N Key:PVLJETXTTWAYEW-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Mizolastine (Mizollen) is a once-daily, non-sedating antihistamine. It blocks H₁ receptors and is commonly fast-acting. It does not prevent the actual release of histamine from mast cells, it only prevents histamine from binding to receptors. Side effects can include dry mouth and throat.